US 11,986,474 B1
Methods for treating heart failure by administering cardiac sarcomere activators
Fady Malik, Burlingame, CA (US)
Assigned to CYTOKINETICS, INCORPORATED, South San Francisco, CA (US)
Filed by Cytokinetics, Incorporated, South San Francisco, CA (US)
Filed on Jun. 27, 2023, as Appl. No. 18/342,387.
Int. Cl. A61K 31/496 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/496 (2013.01) [A61P 9/04 (2018.01)] 30 Claims
 
1. A method of treating heart failure in a subject in need thereof, comprising:
a) administering to the subject a first dose level of a cardiac sarcomere activator (CSA) of about 37.5 mg twice daily for an initial period of time; and
b) administering to the subject a second dose level of the CSA for a second period of time based on the subject's plasma concentration of the CSA determined after administration of the first dose level of the CSA has started;
wherein:
b-i) when the subject's plasma concentration of the CSA is less than 300 ng/mL, the second dose level of the CSA is about 50 mg twice daily;
b-ii) when the subject's plasma concentration of the CSA is greater than or equal to 300 ng/mL and less than or equal to 750 ng/ml, the second dose level of the CSA is about 37.5 mg twice daily; and
b-iii) when the subject's plasma concentration of the CSA is greater than 750 ng/ml, the second dose level of the CSA is about 25 mg twice daily; and
wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof, or a hydrate of any of the foregoing.